Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: FCF 89; Linomide; LS 2616

Latest Information Update: 25 Sep 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Hydroxyquinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Diabetic complications; Gastrointestinal cancer; Hairy cell leukaemia; Leukaemia; Liver disorders; Malignant melanoma; Multiple sclerosis; Prostate cancer; Renal cancer; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 25 Sep 2006 Discontinued - Clinical-Phase-Unknown for Chronic myeloid leukaemia in USA (unspecified route)
  • 25 Sep 2006 Discontinued - Phase-I for Acute myeloid leukaemia in Sweden (PO)
  • 25 Sep 2006 Discontinued - Phase-I for Gastrointestinal cancer in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top